Toremifene Citrate (Fareston) in place of Nolva for PCT?

[jonnydigital]

I am under the impression that Toremifene Citrate is a safer, but less absorbable version of Tamoxifen Citrate. Does anyone have experience in using it in place of it? I cannot seem to find anything that describes how it compares dosage wise (obviously you need much more Toremifene, but how much?) Any insight?

Buy Nolvadex
Buy Clomid

 

[macrophage69alpha]

its not really widely been used.

 

[sparetire]

i have tried it myself, and personally, it works really well. There are a lot of good things about it, i can direct you to a certain place if you pm me that has an open topic about it right now..

 

[macrophage69alpha]

this does not look to promising.

Cancer Chemother Pharmacol. 2000;45(5):402-8. Related Articles, Links


Dose-dependent hormonal effects of toremifene in postmenopausal breast cancer patients.

Ellmen J, Werner D, Hakulinen P, Keiling R, Fargeot P, Falkson G, Bezwoda WR.

Orion Corporation, Orion Pharma, Clinical R & D, Turku, Finland. [email protected]

PURPOSE: The purpose of the study was to compare hormonal effects of three toremifene doses, 20 mg (TOR20), 40 mg (TOR40) and 60 mg (TOR60) administered daily, in postmenopausal women with advanced breast cancer. METHODS: The study was randomized and open label in three parallel groups. Biochemical variables were identified as the serum concentrations of follicle stimulating hormone (FSH), luteinizing hormone (LH) and sex hormone binding globulin (SHBG). The changes were compared with objective clinical responses and to progression-free time. Adverse reactions and liver function test (aspartate aminotransferase, ASAT) were assessed for safety. RESULTS: A total of 260 patients were randomly grouped (90 to TOR20, 81 to TOR40 and 89 to TOR60). Of these patients 29, 29 and 22 completed at least 3 months of treatment and the results were analyzed for biochemical variables. All treatments had intrinsic estrogen agonist activity by decreasing of serum FSH and LH and by increasing of SHBG during the first 3 months (P < 0.01). Dose TOR20 showed slightly longer times to exert maximum estrogenic effects than did the two higher doses. No increases in liver function tests were seen in any of the groups. Objective response rates were 24.4, 39.5 and 32.6% (P = 0.01) and median times-to-progression were 206, 189 and 196 days in TOR20, TOR40 and TOR60, respectively (P = 0.913). Fewer responses were observed in the TOR20 group than in TOR40 (P = 0.05). Adverse events were reported in 19, 23 and 30 patients in the treatment groups (P = 0.20). The most frequently reported events were hot flushes and nausea. These were mostly mild or moderate, and only 1.5% of treatments was discontinued due to toxicity. CONCLUSIONS: Toremifene doses of 40 and 60 mg daily were effective and safe treatments of breast cancer in postmenopausal women, and no differences in their biochemical or clinical effects were seen. Toremifene at 20 mg/day had similar but slightly less potent antiestrogenic and estrogenic effects than the two higher doses.

 

[macrophage69alpha]

^^

 

[macrophage69alpha]

basically that study means that its not a suitable replacement for nolva or clomid (it really has not been established that nolva is as effective as clomid for PCT-- that is still up for debate)

 

[macrophage69alpha]

 

[macrophage69alpha]

as a further note- there is significant debate as to the efficacy of nolva in PCT, clomifen effectiveness is better established

 

[stevebarber]

I am currently using Evista for PCT. That is meant to be v good.

 

[macrophage69alpha]

Eur J Endocrinol. 2004 Apr;150(4):539-46. Related Articles, Links


Effects of raloxifene on gonadotrophins, sex hormones, bone turnover and lipids in healthy elderly men.

Duschek EJ, Gooren LJ, Netelenbos C.

Department of Endocrinology, VU University Medical Centre, Amsterdam, The Netherlands. [email protected]

OBJECTIVE: To explore effects on serum lipids, pituitary-gonadal axis, prostate and bone turnover of the administration of the mixed oestrogen agonist/antagonist raloxifene in healthy elderly men. PARTICIPANTS: Thirty healthy men aged 60-70 years randomly received raloxifene 120 mg/day (n=15) or placebo (n=15) for 3 months. MEASUREMENTS: In this double-blind, placebo-controlled study, serum gonadotrophins, sex hormones, prostate specific antigen (PSA), a marker of bone turnover, urinary hydroxyproline (OHPro) and cholesterol were measured at baseline and after 3 months. RESULTS: Raloxifene significantly increased serum concentrations of LH and FSH (by 29% and 21%), total testosterone (20%), free testosterone (16%) and bioavailable testosterone (not bound to sex hormone-binding globulin (SHBG; 20%). In parallel with testosterone, 17 beta-oestradiol also increased by 21%. SHBG increased by 7%. Total cholesterol (TChol) decreased significantly, from 5.7 to 5.5 mmol/l (P=0.03). Low-density lipoprotein cholesterol (LDL-c) and high-density lipoprotein cholesterol (HDL-c) showed a trend to decrease. Overall, there was no change in urinary OHPro/creatinine ratio as a marker for bone resorption. However, the raloxifene-induced increases in both serum testosterone and 17 beta-oestradiol were significantly related to a lower OHPro/creatinine ratio. Total PSA increased by 17% without significant changes in free PSA or free/total PSA ratio. Participants reported no side effects and raloxifene was well tolerated. CONCLUSION: In healthy elderly man, raloxifene 120 mg/day for 3 months increased LH, FSH and sex steroid hormones. Potentially beneficial effects were the small but significant decrease in TChol and the trend towards a decrease in LDL-c. Negative effects were the trend towards a decrease in HDL-c and the significant increase in serum PSA. A decrease in markers of bone resorption during raloxifene treatment was found only in men with relatively high increases in serum testosterone and 17 beta-oestradiol. Overall, there were no clear beneficial effects of administration of raloxifene to ageing men in this preliminary investigation.